Grace Therapeutics, Inc. (GRCE) Total Assets by Year
Grace Therapeutics, Inc. closed fiscal year 2026 with $66.7M in total assets, $2.8M in total liabilities and $63.9M in shareholder equity. This represents a decrease of 7.4% from the prior fiscal year. The table below carries 8 fiscal years, from 2019 to 2026, and the quarters Grace Therapeutics, Inc. has filed alongside them.
Annual figures, oldest first. Point at a bar to read its period.
GRCE Balance Sheet by Fiscal Year
Figures are as reported in USD. Each change compares the year with the year before it, and each column links to the filing it was taken from.
| Metric | FY26DEF 14A | FY25DEF 14A | FY24DEF 14A | FY2310-K | FY2210-K | FY2110-K | FY2010-K | FY1910-K |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $66.7M-7.4% | $72.0M-1.8% | $73.3M-7.4% | $79.1M-38.5% | $128.6M+105.9% | $62.5M+173.3% | $22.9M-38.1% | $36.9M |
| Total Liabilities | $2.8M-48.8% | $5.4M-53.4% | $11.6M+3.5% | $11.2M-45.1% | $20.4M+199.4% | $6.8M-31.0% | $9.9M-61.9% | $25.9M |
| Total Equity | $63.9M-4.1% | $66.6M+7.9% | $61.7M-9.1% | $68.0M-37.2% | $108.3M+94.5% | $55.7M+328.4% | $13.0M+17.6% | $11.0M |
GRCE Balance Sheet by Quarter
Figures are as reported in USD. Each change compares the quarter with the same quarter a year earlier.
| Metric | Q1'2710-Q | Q4'2610-Q | Q3'2610-Q | Q2'2610-Q | Q1'2610-Q | Q4'2510-K | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q | Q2'2410-Q |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Assets | $50.1M-28.3% | $66.7M-7.4% | $68.5M+11.9% | $66.6M+1.9% | $69.8M+0.1% | $72.0M-1.8% | $61.2M-19.6% | $65.3M-16.4% | $69.7M-4.5% | $73.3M-7.4% | $76.2M-34.8% | $78.2M-35.3% |
| Total Liabilities | $1.9M-70.2% | $2.8M-48.8% | $3.6M-60.4% | $3.8M-59.2% | $6.3M-39.6% | $5.4M-53.4% | $9.1M-21.0% | $9.2M-19.6% | $10.4M+14.8% | $11.6M+3.5% | $11.5M-42.7% | $11.5M-44.7% |
| Total Equity | $48.2M-24.1% | $63.9M-4.1% | $64.9M+24.5% | $62.8M+11.9% | $63.5M+7.1% | $66.6M+7.9% | $52.1M-19.4% | $56.1M-15.9% | $59.4M-7.3% | $61.7M-9.1% | $64.7M-33.1% | $66.7M-33.4% |
What total assets means
Total assets is everything the company owns on the balance sheet date, total liabilities is everything it owes, and the difference between them is the equity that belongs to shareholders.
More Grace Therapeutics, Inc. financials
Frequently Asked Questions
What was Grace Therapeutics, Inc.'s total assets in fiscal year 2026?
Grace Therapeutics, Inc. closed fiscal year 2026 with $66.7M in total assets, $2.8M in total liabilities and $63.9M in shareholder equity.
How fast is Grace Therapeutics, Inc.'s total assets growing?
Grace Therapeutics, Inc. (GRCE) total assets fell by 7.4% year over year, from $72.0M to $66.7M in fiscal year 2026.
How has Grace Therapeutics, Inc.'s total assets changed over the years?
Across the 8 fiscal years this page covers, Grace Therapeutics, Inc. (GRCE) total assets went from $36.9M in fiscal year 2019 to $66.7M in fiscal year 2026.
What was Grace Therapeutics, Inc.'s total assets in the most recent quarter?
Grace Therapeutics, Inc. (GRCE) reported $50.1M in total assets in Q1 2027. This represents a decrease of 28.3% from the same quarter a year earlier.
What does total assets mean on a financial statement?
Total assets is everything the company owns on the balance sheet date, total liabilities is everything it owes, and the difference between them is the equity that belongs to shareholders. This page lists what Grace Therapeutics, Inc. (GRCE) reported on that line in every period on record.